{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:52:52Z","timestamp":1774288372451,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejso.2024.108352","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:48:32Z","timestamp":1713368912000},"page":"108352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4821-1897","authenticated-orcid":false,"given":"T.M.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-2979","authenticated-orcid":false,"given":"L.","family":"Randle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"McGreevy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-4162","authenticated-orcid":false,"given":"L.","family":"O\u2019leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Diaz-Neito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Greenhalf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Goldring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.ejso.2024.108352_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.ejso.2024.108352_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00534-009-0208-1","article-title":"Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality","volume":"17","author":"Hirano","year":"2010","journal-title":"J\u00a0Hepato-Biliary-Pancreatic Sci"},{"issue":"10","key":"10.1016\/j.ejso.2024.108352_bib3","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.hpb.2021.03.016","article-title":"Surgical morbidity in the first year after resection for perihilar cholangiocarcinoma","volume":"23","author":"van Keulen","year":"2021","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ejso.2024.108352_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101875","article-title":"Long-term morbidity after surgery for perihilar cholangiocarcinoma: a cohort study","volume":"45","author":"Gilbert","year":"2022","journal-title":"Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2024.108352_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"suppl 5","key":"10.1016\/j.ejso.2024.108352_bib6","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2024.108352_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2024.108352_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2024.108352_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular bases of chemoresistance in cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr Drug Targets"},{"issue":"6","key":"10.1016\/j.ejso.2024.108352_bib10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","article-title":"Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection","volume":"221","author":"Groot Koerkamp","year":"2015","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1245\/s10434-015-4642-9","article-title":"Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection","volume":"23","author":"Spolverato","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108352_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108352_bib14","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejso.2019.04.002","article-title":"Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged","volume":"45","author":"Alabraba","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-015-0203-x","article-title":"Next-generation sequencing to guide cancer therapy","volume":"7","author":"Gagan","year":"2015","journal-title":"Genome Med"},{"key":"10.1016\/j.ejso.2024.108352_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108352_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"7457","key":"10.1016\/j.ejso.2024.108352_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejso.2024.108352_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib22","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-023-33096-0","article-title":"Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways","volume":"13","author":"Quinn","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ejso.2024.108352_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100505","article-title":"Role of molecular genetics in the clinical management of cholangiocarcinoma","volume":"7","author":"Normanno","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ejso.2024.108352_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100503","article-title":"Advances in the systemic treatment of therapeutic approaches in biliary tract cancer","volume":"7","author":"Mirallas","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejso.2024.108352_bib25","first-page":"1","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","author":"Jain","year":"2018","journal-title":"JCO Prec Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2024.108352_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O\u2019Neil","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.ejso.2024.108352_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108352_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","article-title":"Biliary tract cancer: state of the art and potential role of DNA damage repair","volume":"70","author":"Lamarca","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ajcp\/aqz199","article-title":"Mismatch repair protein deficiency\/microsatellite instability is rare in cholangiocarcinomas and associated with distinctive morphologies","volume":"153","author":"Ju","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"S1","key":"10.1016\/j.ejso.2024.108352_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/liv.14085","article-title":"Molecular perturbations in cholangiocarcinoma: is it time for precision medicine?","volume":"39","author":"Braconi","year":"2019","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.ejso.2024.108352_bib32","first-page":"13246","article-title":"Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy","volume":"13","author":"Sarantis","year":"2021","journal-title":"Am J Transl Res"},{"issue":"10","key":"10.1016\/j.ejso.2024.108352_bib33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.ejso.2024.108352_bib34","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2024.108352_bib36","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"3","key":"10.1016\/j.ejso.2024.108352_bib38","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"43","key":"10.1016\/j.ejso.2024.108352_bib39","doi-asserted-by":"crossref","first-page":"12250","DOI":"10.1073\/pnas.1600067113","article-title":"Notch3 drives development and progression of cholangiocarcinoma","volume":"113","author":"Guest","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1186\/s12885-016-2919-4","article-title":"Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties","volume":"16","author":"Aoki","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2024.108352_bib41","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3892\/or.2014.3123","article-title":"Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in\u00a0vitro","volume":"31","author":"Wu","year":"2014","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/j.ejso.2024.108352_bib42","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1172\/JCI63065","article-title":"Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes","volume":"122","author":"Sekiya","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"24","key":"10.1016\/j.ejso.2024.108352_bib43","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1038\/s41388-018-0188-1","article-title":"Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejso.2024.108352_bib44","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting","volume":"59","author":"Sirica","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13087","article-title":"Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma","volume":"49","author":"Tamma","year":"2019","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.ejso.2024.108352_bib46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2015.11.011","article-title":"Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche","volume":"64","author":"Govaere","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.ejso.2024.108352_bib47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2018.00414","article-title":"Alteration of the antitumor immune response by cancer-associated fibroblasts","volume":"9","author":"Ziani","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ejso.2024.108352_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113310","article-title":"IDH signalling pathway in cholangiocarcinoma: from biological rationale to therapeutic targeting","volume":"12","author":"Salati","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejso.2024.108352_bib49","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2024.108352_bib50","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.108352_bib52","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.ejso.2024.108352_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233929","article-title":"FGFR inhibitors in cholangiocarcinoma-A novel yet primary approach: where do we stand now and where to head next in targeting this Axis?","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejso.2024.108352_bib55","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2021.39.15_suppl.4086","article-title":"Pemigatinib for previously treated locally advanced\/metastatic cholangiocarcinoma (CCA): update of FIGHT-202","volume":"39","author":"Abou-Alfa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ejso.2024.108352_bib56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108352_bib57","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ejso.2024.108352_bib58","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion\u2013positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ejso.2024.108352_bib59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.ejso.2024.108352_bib60","doi-asserted-by":"crossref","first-page":"TPS600","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS600","volume":"38","author":"Borad","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"46","key":"10.1016\/j.ejso.2024.108352_bib61","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.3748\/wjg.14.7033","article-title":"Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma","volume":"14","author":"Sirica","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108352_bib62","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib63","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ejso.2024.108352_bib64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108352_bib65","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-Na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2024.108352_bib66","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"de Vries","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.ejso.2024.108352_bib67","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2024.108352_bib69","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820983013","article-title":"Targeting BRAF-mutant biliary tract cancer: recent advances and future challenges","volume":"27","author":"Rizzo","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejso.2024.108352_bib71","article-title":"BRAF mutation in Chinese biliary tract cancer patients","volume":"38","author":"Li","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2024.108352_bib72","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2024.108352_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/107327481402100307","article-title":"BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies","volume":"21","author":"Hall","year":"2014","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.ejso.2024.108352_bib74","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"4_suppl","key":"10.1016\/j.ejso.2024.108352_bib75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial","volume":"37","author":"Wainberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108352_bib76","article-title":"PARP inhibitors in biliary tract cancer: a new kid on the block?","volume":"7","author":"Ricci","year":"2020","journal-title":"Medicines (Basel)"},{"issue":"4","key":"10.1016\/j.ejso.2024.108352_bib77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ejso.2024.108352_bib78","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without Veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108352_bib79","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108352_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091463","article-title":"DNA damage response inhibitors in cholangiocarcinoma: current progress and perspectives","volume":"11","author":"G\u00f6n\u00fcl Geyik","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108352_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2024.108352_bib83","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.ejso.2024.108352_bib84","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejso.2024.108352_bib85","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ejso.2024.108352_bib86","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108352_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072105","article-title":"Precision oncology targets in biliary tract cancer","volume":"15","author":"Farha","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejso.2024.108352_bib88","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2024.108352_bib89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2024.108352_bib90","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of Entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2024.108352_bib91","first-page":"2017","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2024.108352_bib92","unstructured":"Bridgewater, J. ABC-10 (SAFIR ABC-10 Precision Medicine). Available from: https:\/\/www.ctc.ucl.ac.uk\/TrialDetails.aspx?Trial=188&."},{"issue":"30","key":"10.1016\/j.ejso.2024.108352_bib93","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"issue":"30","key":"10.1016\/j.ejso.2024.108352_bib94","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324004049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324004049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:46:53Z","timestamp":1740124013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324004049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0748798324004049"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108352","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108352"}}